Openbookopenbook
Equity
Scynexis Inc(SCYX)
USD --+0.00%
Reward47Moderate
Risk77High
📊75%Data
Revenue down 49% YoY
SCYX
+0.0 · +0.00%
USD · NASDAQ
Scynexis Inc | Healthcare
Earnings Deterioration
Market Cap:31.47M
ℹ️
Reward Rating
47
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
77
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SCYX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $3.67.

What is Scynexis Inc?

, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.

SCYX · Verdict

Moderate reward · high risk

SCYX's standout is valuation; cash flow and balance sheet weigh on the picture.

Based on 88% data coverage

SCYX · Verdict

What’s working & what to watch

Strengths 1

  • Valuation74/100

    P/E 3.5×

Watchouts 5

  • Cash flow9/100

    -641% free-cash-flow margin

  • Balance sheet26/100

    Current ratio 3.00

  • Profitability32/100

    -568% net margin · -53% ROE

  • Volatility35/100

    Below average

  • Growth43/100

    Rev -34.2% CAGR · earnings -13.5%

Model-based scoring. For information only — not financial advice.

What is Scynexis Inc?

, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 31.47M.

Financial Highlights

Investment Breakdown

📈 Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (47)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap31.47M
P/E RatioN/A
Dividend YieldN/A
52 Week High1.31
52 Week Low0.565
Last AnnualDecember
IPO Date5/2/2014
IncorporatedUSA
Shares Outstanding42M
No. of Employees28
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
Beta1.34
CurrencyUSD
Websitewww.scynexis.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.